Cell line · CVCL_1473
Papers51
1 to 20 of 51
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer. | Transl Lung Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Autophagy-Targeting Stapled Peptide Utilizes Macropinocytosis for Cell Entry to Potentiate Anti-Proliferative Autosis in Small-Cell Lung Cancer. | Pharmaceutics | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A public data-based molecular classification of small cell lung cancer by neuroactive signaling networks unveils distinct microenvironment landscapes and immunotherapy-related prognostic biomarkers. | Transl Lung Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Molecular mechanisms underlying HRK interaction with BCL-XL and BCL-2 reveal specificity determinants for BH3 mimetics. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells. | Cancer Res Treat | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Jumonji histone demethylases are therapeutic targets in small cell lung cancer. | Oncogene | 2024 | Cellosaurus cites it | PubMed | |
| Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Replication stress defines distinct molecular subtypes across cancers. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. | Cell Rep Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. | Clin Epigenetics | 2020 | Cellosaurus cites it | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. | J Cell Biochem | 2020 | Cellosaurus cites it | PubMed | |
| An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. | Cancer Cell | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1473/papers